Divamics Highlights Key Programs and Expands Footprint at JPM Week 2026

At JPM Week 2026 in San Francisco, Divamics, an AI-driven biotechnology innovator, showcased significant advancements in its portfolio. The spotlight was on its lead program, DVI-001, devoted to autoimmune therapies, and the newly introduced metabolic project, DVI-004. These developments underscore Divamics’ commitment to bridging AI technology with clinical applications, promising to reshape early-stage R&D dynamics in biotechnology.

Founded in 2021, Divamics leverages cutting-edge AI and molecular dynamics to revolutionize drug discovery processes. Under the leadership of CEO Dr. John Zheng and co-founder Dr. Hao Liu, the company combines U.S. scientific expertise with China’s rapid biotech progression. The firm’s approach integrates rigorous academic foundations with practical commercial applications, demonstrated through collaborations like the one with BrightGene. These partnerships and Divamics’ technological capabilities were validated by significant interest during JPM Week, including over 50 meetings with global biopharma stakeholders. The company, guided by Dr. Kenneth M. Merz Jr., a luminary in computational chemistry, is strategically positioned across Asia with hubs in Suzhou, Shanghai, Beijing, and Singapore to foster international R&D partnerships.

Divamics is set to influence the biotech industry profoundly by blending AI with molecular dynamics for precision-driven drug discovery. Its recent announcements at JPM Week reinforce its innovative stance and global market aspirations, promising enhanced R&D efficiency and new collaborations that could reshape disease treatment paradigms worldwide.